| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: present invention refers to a crystalline salt form representing a sulphate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxypropionyl)amino]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)benzamide or its hydrate which are used as mu-opioid receptor antagonists, to a based pharmaceutical composition, to applying them for preparing a drug, as well as to a method of treating, improving gastrointestinal motility and mu-opioid receptor antagonisation. n EFFECT: invention refers to versions of the method for preparing the crystalline sulphate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxypropionyl)amino]ethyl}-8-azabicyclo[3,2,1]oct-3-yl)benzamide and to a bisulphite adduct of benzene ester of N-cyclohexylmethyl-(2-oxoethyl)carbamic acid. n 26 cl, 26 ex, 6 dwg |